Company Leadership Changes - Samir R. Patel, M.D. has been appointed as Chief Executive Officer of Akari Therapeutics, effective December 16, 2024, after serving as interim CEO since May 2024 [1][2] - Abizer Gaslightwala has been appointed to the Board of Directors, effective December 16, 2024, following the resignation of Michael Grissinger from the Board [1][7] Strategic Focus and Growth - Under Dr. Patel's leadership, the company successfully closed a merger with Peak Bio in November 2024 and is now focusing on streamlining operations and prioritizing its portfolio, particularly its antibody-drug conjugate (ADC) platform [2] - Dr. Patel expressed commitment to building momentum and driving shareholder value in both the near and long term [2] Leadership Background - Dr. Patel has over 20 years of experience in life sciences, including founding SPEC Pharma, LLC, and holding various roles in Medical Affairs at Centocor, Inc. [4] - Abizer Gaslightwala brings over 25 years of experience in the biotechnology and pharmaceutical industry, currently serving as Senior Vice President and Franchise Head for Oncology at Jazz Pharmaceuticals, overseeing a portfolio with total annual sales of $1 billion [6][8] Company Overview - Akari Therapeutics is a biotechnology company focused on developing advanced therapies for autoimmune, oncology, and inflammatory diseases, with lead assets including investigational nomacopan and an ADC platform [10][11]
Akari Therapeutics Announces Key Leadership Appointments